ReviewFrontiers in immunology2014
Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma.
Review in Frontiers in immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- European Myeloma Network guidelines for the management of multiple myeloma-related complications.Haematologica · 2015Guideline
- Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial.Clinical lymphoma, myeloma & leukemia · 2017Trial
- Multiple eruptive dermatofibromas occurring in association with monoclonal gammopathy of undetermined significance: A case report.SAGE open medical case reports · 2026Article
- Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study.Leukemia · 2025Article
- Kidney Transplantation in Patients with Multiple Myeloma: Current Evidence, Challenges, and Future Directions.International journal of molecular sciences · 2025Review
- Advanced disease and CD8Frontiers in immunology · 2025Article
- COVID-19-Associated Cold Agglutinin Syndrome and Hemophagocytosis in a Patient with Monoclonal Gammopathy of Undetermined Significance.Mediterranean journal of hematology and infectious diseases · 2025Article
- Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma.International journal of hematology · 2024Article
- Fatal Human Rabies Infection With Suspected Host-Mediated Failure of Post-Exposure Prophylaxis Following a Recognized Zoonotic Exposure-Minnesota, 2021.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Review
- Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma.Clinical infection in practice · 2023Article
- Article
- Concurrent Cytomegalovirus Colitis and Gastrointestinal Amyloidosis as Initial Presentation of Multiple Myeloma.ACG case reports journal · 2022Article
- Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients.Leukemia · 2022Review
- Aseptic abscess in the abdominal wall accompanied by monoclonal gammopathy simulating the local recurrence of rectal cancer: A case report.World journal of clinical cases · 2022Article
- Machine learning-based infection prediction model for newly diagnosed multiple myeloma patients.Frontiers in neuroinformatics · 2022Article
- Distinct phenotype of neutrophil, monocyte, and eosinophil populations indicates altered myelopoiesis in a subset of patients with multiple myeloma.Frontiers in oncology · 2022Article
- Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response.Oncoimmunology · 2022Article
- Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study.Blood cancer journal · 2021Article
- [Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Moraxella Bacteremia in Cancer Patients.Cureus · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The plasma cell proliferative disorders monoclonal gammopathy of undetermined significance (MGUS) and malignant multiple myeloma (MM) are characterized by an accumulation of transformed clonal plasma cells in the bone marrow and production of monoclonal immunoglobulin. They typically affect an older population, with median age of diagnosis of approximately 70 years. In both disorders, there is an increased risk of infection due to the immunosuppressive effects of disease and conjointly of therapy in MM, and response to vaccination to counter infection is compromised. The underlying factors in a weakened immune response in MGUS and MM are as yet not fully understood. A confounding factor is the onset of normal aging, which quantitatively and qualitatively hampers humoral immunity to affect response to infection and vaccination. In this review, we examine the status of immune alterations in MGUS and MM and set these against normal aging immune responses. We focus primarily on quantitative and functional aspects of B-cell immunity. Furthermore, we review the current knowledge relating to susceptibility to infectious disease in MGUS and MM, and how efficacy of conventional vaccination is affected by proliferative disease-related and therapy-related factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.